Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18878943 | 0.86 | MAPT (0.52) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL20265346 | 0.79 | MAPT (0.70) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL3156796 | 0.79 | MAPT (0.63) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| Quinoline SCHEMBL28127501 | 0.78 | ALDH1A1 (0.57) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL17776539 | 0.76 | MEN1 (0.64) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL30936970 | 0.76 | GLO1 (0.66) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL4546341 | 0.75 | TDP1 (0.62) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL27857992 | 0.75 | ALDH1A1 (0.63) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL2736333 | 0.73 | MEN1 (0.62) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28172351 | 0.73 | TDP1 (0.60) | MAPTALDH1A1KDM4EPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| WO-2021226519-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3896064-A1 | 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS | Gilead Sciences, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | disclosed |
| EP-3456717-A1 | TABLETS CONTAINING 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
| EP-2310389-B1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647675-B2 | Biaryl derivative and medicine containing same | MAN2B1, CBR3, MANBA | MAPT 4703/4885ALDH1A1 2994/4885KDM4E 2642/4885 |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | MAN2B1, CBR3, MANBA | MAPT 4703/4885ALDH1A1 2994/4885KDM4E 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.